1. Scrip
  2. >>Business
  3. >>Earnings

Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year

 
• By Jessica Merrill

Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.

vaccine
Pfizer expects new vaccines to deliver a boost to revenues • Source: Shutterstock

Pfizer Inc. has several launches planned for the second half of the year, including the new vaccine Abrysvo for respiratory syncytial virus (RSV) in older adults, the bispecific antibody elranatamab for multiple myeloma, etrasimod for ulcerative colitis and expansion of the pneumococcal vaccine Prevnar 20 to the pediatric population – a larger commercial opportunity versus adults.

Pfizer CEO Albert Bourla told investors during the company’s first quarter sales and earnings call on 2 May that revenues excluding COVID-19 products are expected to grow faster in the second

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.